Skip to main content

Published locations for EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetes

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetes

User login

  • Reset your password
  • /content/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients-type-2-diabetes
  • /familypracticenews/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients
  • /internalmedicinenews/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk
  • /clinicalendocrinologynews/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk
  • /anticoagulationhub/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients
  • /diabeteshub/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients-type-2
  • /ecardiologynews/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients
  • /cardiology/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients-type-2
  • /endocrinology/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients-type
  • /internalmedicine/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients
  • /familymedicine/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients-type
  • /chestphysician/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk-patients-type
  • /type-2-diabetes-icymi/article/102750/diabetes/easd-sglt2-inhibitor-empagliflozin-cuts-cv-risk